Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Kidney Neoplasms 2Carcinoma, Renal Cell 2Unspecified Adult Solid Tumor, Protocol Specific 1Sarcoma, Kaposi 1Melanoma 1HIV Infections 1Acquired Immunodeficiency Syndrome 1

Interventions

Irinotecan 15Gemcitabine 14Paclitaxel 13Cisplatin 13alvocidib 11Oxaliplatin 9Fluorouracil 9Taxes 7Leucovorin 7Carboplatin 7Bortezomib 73-aminopyridine-2-carboxaldehyde thiosemicarbazone 7tanespimycin 5Vorinostat 5Early Intervention, Educational 57-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine 4Topotecan 3Sorafenib 3Doxorubicin 3Docetaxel 3Capecitabine 3Bevacizumab 37-hydroxystaurosporine 3temsirolimus 2sargramostim 2ixabepilone 2eribulin 2aldesleukin 2VNP 20009 2Trastuzumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Unspecified Adult Solid Tumor, Protocol Specific × Muromonab-CD3 × Clear all
NCT00002482 2013-11-06

Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer

National Cancer Institute (NCI)

Phase 1/2 Unknown
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

Data powered by HemOnc (CC BY 4.0) Colophon âš¡